Literature DB >> 18304209

Pharmacokinetic(s) matters: stroke treatment et cetera.

J M Ritter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18304209      PMCID： PMC2291240          DOI： 10.1111/j.1365-2125.2008.03152.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?

Authors:  Lise Aagaard; Birthe Soendergaard; Doris I Stenver; Ebba Holme Hansen
Journal:  Br J Clin Pharmacol       Date:  2007-10-24       Impact factor: 4.335

2.  Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects.

Authors:  Wiesław J Cubała; Jerzy Landowski; Hubert M Wichowicz
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

3.  Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

Authors:  Reza Khosravan; Brian Grabowski; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

Review 4.  Animal models of stroke: do they have value for discovering neuroprotective agents?

Authors:  A Richard Green; Tomas Odergren; Tim Ashwood
Journal:  Trends Pharmacol Sci       Date:  2003-08       Impact factor: 14.819

5.  Evaluation of medication reviews conducted by community pharmacists: a quantitative analysis of documented issues and recommendations.

Authors:  J Krska; A J Avery
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

6.  Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation.

Authors:  Syed H R Mazhar; Nahlah E Ismail; Duncan A G Newton; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

7.  Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

Authors:  Pooja Gupta; Vandana Roy; Gulshan Rai Sethi; Tarun Kumar Mishra
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

8.  The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

Authors:  Yan-Ling He; Ron Sabo; Joelle Campestrini; Yibin Wang; Gilles-Jacques Riviere; Jace C Nielsen; Mitchell Rosenberg; Monica Ligueros-Saylan; Dan Howard; William P Dole
Journal:  Br J Clin Pharmacol       Date:  2007-10-24       Impact factor: 4.335

9.  A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.

Authors:  H C A Emsley; C J Smith; R F Georgiou; A Vail; S J Hopkins; N J Rothwell; P J Tyrrell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

10.  Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage.

Authors:  Ivelina Gueorguieva; Simon R Clark; Catherine J McMahon; Sylvia Scarth; Nancy J Rothwell; Pippa J Tyrrell; Pippa J Tyrell; Stephen J Hopkins; Malcolm Rowland
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335
View more
  1 in total

1.  Combination therapy for cerebral ischemia: do progesterone and noscapine provide better neuroprotection than either alone in the treatment?

Authors:  Manisha Kawadkar; Avinash S Mandloi; Nidhi Singh; Rajesh Mukharjee; Vipin V Dhote
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-06       Impact factor: 3.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.